might help to maintain patency of the dialysis circuit for several hours or days with little or no need for anticoagulation. Alternatively, the recent development of newer oral anticoagulants ...

At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively.At 12 ...

Systems announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy trial ...

Merit Medical Systems, Inc. announced the publication of the 6-month results from the randomized arm of the WAVE trial of arterio ...

The WRAPSODY CIE is designed to help clinicians restore vascular access in patients on hemodialysis who experience stenosis in their venous outflow circuit. The WAVE trial is a multicenter ...